Key Points Roche's leading weight loss and diabetes candidate has posted excellent Phase 2 clinical trial results. The medicine could carve out a solid niche in this field. Roche may still not be able to take the lead from Eli Lilly, but there are other reasons to invest in the company. 10 stocks we like better than Roche Holding AG › Novo Nordisk (NYSE:NVO) has been a pioneer in the market for weight loss drugs, but Eli Lilly (NYSE:LLY) has since emerged as the leader. Both drugmakers have deep pipelines that could allow them to remain ahead of their competitors in the coming years as the anti-obesity area continues to expand rapidly. But could another pharmaceutical giant eventually take the lead?
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.